We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has approved Shire’s once-daily drug Intuniv for attention deficit hyperactivity disorder (ADHD) in extended-release tablets for children and adolescents age 6 to 17.